
Robyn Young MD
Breast Cancer, Hematologic Oncology
Director of Breast Cancer at The Center for Cancer and Blood Disorders
Join to view full profile
800 W Magnolia AveFort Worth, TX 76104
Phone+1 817-759-7000
Fax+1 817-759-7027
Dr. Young is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1993 - 1995
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1990 - 1993
McGovern Medical School at UTHealthClass of 1990
Certifications & Licensure
TX State Medical License 1991 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2015
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Publications & Presentations
PubMed
- 8 citationsDESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid, Carey K Anders
Clinical Cancer Research. 2026-03-16 - 143 citationsLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark
Annals of Oncology. 2022-04-01 - 9 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: